We found that 28.5% of human pluripotent stem cell (hPSC) samples tested using the iCS-digital PSC test are abnormal

iCS-digital: A method for monitoring hPSC genome integrity that detects more than 90% of recurrent genomic abnormalities. The test is rapid (2-3 days), convenient (full service), straightforward, and can be performed using cell culture supernatant. It is particularly suitable for the routine monitoring of cell lines in culture and for screening genetically stable clones (e.g., CRISPR-edited iPSC clones, patient-derived iPSC clones…).

Latest news

discover and share

The discovery and recent advances in the CRISPR/Cas9 gene-editing technology have profoundly reshaped the field of genome engineering and allowed the generation of a wide range of mutant cell lines at an unprecedented rate. However, CRISPR/Cas9 gene editing in hPSCs can also pose a threat to the overall genomic integrity. Why? To know more, have a look at our July newsletter!

Stem cells are the heart of many of tomorrow personalized therapies. Join us at the most comprehensive meeting in stem cell science, the ISSCR 2021. It will take place virtually from 21 to 26 June 2021. Discover our services for your stem cell research projects and meet us at our booth during this virtual event! We are eager to answer any questions you might have.

Stay informed

Subscribe to our newsletter

Subscribe to our newsletter
By subscribing, you authorize Stem Genomics to register your email address. We will only use your email address to send you our newsletter.